Learn why early notified-body engagement is critical for combination products, including design rationale, risk controls, validation evidence and traceable documentation ahead of submission.

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new ...

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, ...

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting ...

Lonza has nominated Pearl Huang as an independent member of its Board of Directors, bringing extensive pharmaceutical and ...

At Booth 11F93 in Hall 11, the company will not only be showcasing its new look, it will also present solutions for sensitive ...

Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the ...

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments ...

Partnership combines complementary expertise to help pharmaceutical formulators address complex solid oral dose development ...

Helen explains how the NSF QP Alumni community helps Qualified Persons stay current through regulatory updates, peer discussions and shared experience, offering practical insight into evolving industr ...

The expansion includes new fluorinated sugars and GMP-grade Poly(I:C), supporting glycoengineering, bioproduction, vaccine ...

The Swiss pharma company has agreed to pay $575m upfront for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell ...